EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV ‐associated chronic lung disease

Trym Thune Flygel, Dan Hameiri-Bowen, Victoria Simms, Sarah Rowland-Jones, Rashida Abbas Ferrand, Tsitsi Bandason, Louis-Marie Yindom, Jon Øyvind Odland, Jorunn Pauline Cavanagh, Trond Flaegstad, Evgeniya Sovershaeva

HIV Medicine · 2024

DOI: 10.1111/hiv.13565 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift HIV Medicine, 2024. Verfasst von Trym Thune Flygel und 10 weiteren Autor:innen. Beteiligte Einrichtung: Paediatric Research Group, Department of Clinical Medicine, Faculty of Health sciences, UiT - The Arctic University of Norway, Tromsø, Norway. Hauptthemen laut MEDLINE: HIV Infections, Lung Diseases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Medical Research Council UK, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Chronic lung disease is a recognized complication in children with HIV. Acute respiratory exacerbations (ARE) are common among this group and cause significant morbidity. Exhaled nitric oxide (eNO) is a known marker of local airway inflammation. We investigated the association between eNO and ARE, biomarkers of systemic inflammation, and the effect of azithromycin on eNO levels.

Methods

Individuals aged 6–19 years with HIV‐associated chronic lung disease in Harare, Zimbabwe, were enrolled in a placebo‐controlled randomized trial investigating the effect of 48‐week azithromycin treatment on lung function and ARE. eNO levels and biomarkers were measured at inclusion and after treatment in a consecutively enrolled subset of participants. Linear regression and generalized linear models were used to study associations between eNO and ARE, biomarkers, and the effect of azithromycin on eNO levels.

Results

In total, 172 participants were included in this sub‐study, 86 from the placebo group and 86 from the azithromycin group. Participants experiencing at least one ARE during follow‐up had significantly higher eNO levels at baseline than participants who did not (geometric mean ratio 1.13, 95% confidence interval [CI] 1.03–1.24, p = 0.015), adjusted for trial arm, age, sex and history of tuberculosis. Matrix metalloproteinase (MMP)‐3, ‐7, and ‐10 were significantly associated with higher baseline eNO levels. At 48 weeks, azithromycin treatment did not affect eNO levels (geometric mean ratio 0.86, 95% CI 0.72–1.03, p = 0.103).

Conclusion

Higher baseline eNO levels were a risk factor for ARE. eNO was associated with proinflammatory biomarkers previously found to contribute to the development of chronic lung disease. The potential use of eNO as a marker of inflammation and risk factor for ARE in HIV‐associated chronic lung disease needs further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsLung DiseasesChildHumansAzithromycinBiomarkersBreath TestsInflammationNitric OxideZimbabweAdolescentYoung Adult

Stichwörter der Autor:innen

AfricaHIVbiomarkerschronic lung diseaseexhaled nitric oxideinflammation

Substanzen

AzithromycinBiomarkersNitric Oxide

Autor:innen und Institutionen

  • Paediatric Research Group, Department of Clinical Medicine, Faculty of Health sciences, UiT - The Arctic University of Norway, Tromsø, Norway.
  • Department of Paediatrics, University Hospital of North Norway, Tromsø, Norway.
  • Nuffield Department of Medicine, University of Oxford, Oxford, UK.
  • Department of Infectious Disease Epidemiology, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
  • Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, UK.
  • Biomedical Research and Training Institute, Harare, Zimbabwe.

Förderung

  • Wellcome Trust
  • Medical Research Council UK
  • Norges Forskningsråd
  • Helse Nord RHF
  • Medical Research Council
  • European Commission

Zitieren

APA

Flygel, T. T., Hameiri-Bowen, D., Simms, V., Rowland-Jones, S., Ferrand, R. A., Bandason, T., Yindom, L. M., Odland, J. Ø., Cavanagh, J. P., Flaegstad, T., & Sovershaeva, E. (2024). Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV ‐associated chronic lung disease. HIV Medicine. https://doi.org/10.1111/hiv.13565

Vancouver

Flygel TT, Hameiri-Bowen D, Simms V, Rowland-Jones S, Ferrand RA, Bandason T, et al. Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV ‐associated chronic lung disease. HIV Medicine. 2024. doi:10.1111/hiv.13565

BibTeX
@article{Flygel2024,
  author = {Flygel, Trym Thune and Hameiri-Bowen, Dan and Simms, Victoria and Rowland-Jones, Sarah and Ferrand, Rashida Abbas and Bandason, Tsitsi and Yindom, Louis-Marie and Odland, Jon Øyvind and Cavanagh, Jorunn Pauline and Flaegstad, Trond and Sovershaeva, Evgeniya},
  title = {Exhaled nitric oxide is associated with inflammatory biomarkers and risk of acute respiratory exacerbations in children with HIV ‐associated chronic lung disease},
  journal = {HIV Medicine},
  year = {2024},
  doi = {10.1111/hiv.13565}
}
Kostenlos starten →